v3.26.1
Shareholders’ Equity (Tables)
12 Months Ended
Dec. 31, 2025
Shareholders’ Equity [Abstract]  
Schedule of Expenses Recognized

Expenses recognized in the financial statements:

 

   Year Ended December 31, 
   2025   2024   2023 
             
Research and development expenses  $365   $41   $83 
General and administrative expenses   945    10    17 
Total  $1,310    51   $100 
Schedule of Share Options Outstanding and Exercisable

A summary of the Company’s share options outstanding and exercisable as of December 31, 2025 and 2024 and changes during the year then ended are presented below:

 

   2025 
   Number of
share
option
   Weighted
average
exercise
price
 
         
Share options outstanding at beginning of year   164   $1,508 
           
Share options outstanding at year end   164    1,508 
           
Share options exercisable at year end   164   $1,508 
Schedule of Fair Value of Share Options

The fair value of the Company’s share options granted was estimated using the Black-Scholes option pricing model using the following range assumptions:

 

Description   2023  
       
Risk-free interest rate     4.00% - 4.22 %
Expected volatility     90.02% - 94.24 %
Dividend yield     0  
Contractual life     5 - 7  
Exercise price     0.02 – 1.133